Drugs / 2L-PEG/Asc
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05249335 Comparator | Feb 2022 → Feb 2024 | colonic disorder | Pharmbio Korea Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2L-PEG/Asc | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05249335 ↗ |
| Known as | 2 L-polyethylene glycol/ascorbate | “BACKGROUND: We compared the efficacy, tolerability, and safety of oral sulfate tablets (OST, which contains simethicone) and 2 L-polyethylene glycol/ascorbate (2 L-PEG/Asc)...” PMID 38492010 ↗ Mar 2024 |